If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Giulia Valeria Bianchi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 60 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Cazzaniga, M. E., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Gianni, L., Michelotti, A., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 31 others, La Verde, N., Bianchi, G. V., Artale, S., Blasi, L., De Laurentiis, M., Atzori, F., Turletti, A., Porpiglia, M., Santini, D., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Giordano, M., Donadio, M., Biganzoli, L., Del Mastro, L., Bisagni, G., Livi, L., Natoli, C., Montemurro, F., Riccardi, F., Romagnoli, E., Marchetti, P., Torri, V., Pronzato, P. & Mustacchi, G., Jan 1 2020, In : Breast Care. 15, p. 30-37 8 p.

Research output: Contribution to journalArticle

  • De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study

    Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De Salvo, G. L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C. A., Moretti, G., Griguolo, G., Vicini, R., Prat, A. & Conte, P. F., Jun 1 2019, In : Annals of Oncology. 30, 6, p. 921-926 6 p.

    Research output: Contribution to journalArticle

  • De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

    Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De Salvo, G. L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C. A., Moretti, G., Griguolo, G., Vicini, R., Prat, A. & Conte, P. F., Jun 1 2019, In : Annals of Oncology. 30, 6, p. 921-926 6 p.

    Research output: Contribution to journalArticle

    Open Access
  • De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study

    Guarneri, V., Dieci, M. V., Bisagni, G., Frassoldati, A., Bianchi, G. V., De Salvo, G. L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C. A., Moretti, G., Griguolo, G., Vicini, R., Prat, A. & Conte, P. F., 2019, In : Annals of Oncology. 30, 6, p. 921-926 6 p.

    Research output: Contribution to journalArticle

    Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

    Cosimo, S. D., Verde, N. L., Moretti, A., Cazzaniga, M. E., Generali, D., Bianchi, G. V., Mariani, L., Torri, V., Crippa, F., Paolini, B., Scaperrotta, G., De Santis, M. C., Nicola, M. D., Apolone, G., Gulino, A., Tripodo, C., Colombo, M. P., Folli, S. & de Braud, F., Jan 1 2019, In : PLoS One. 14, 8, e0220644.

    Research output: Contribution to journalArticle

    Open Access